Last reviewed · How we verify
Iron Fumarate (FERROUS FUMARATE)
Ferrous Fumarate, marketed by Pfizer, is an established treatment for Iron Deficiency Anemia, competing in a well-established market segment with other iron supplements. Its key strength lies in its mechanism of providing essential iron to support healthy red blood cell production, aligning with the primary therapeutic need. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | FERROUS FUMARATE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1986 |
Approved indications
- Iron Deficiency Anemia
- Folate Deficiency Anemia
- Iron Deficiency in Pregnancy
- Folic Acid Maintenance in Pregnancy
Common side effects
- gastrointestinal intolerance
- allergic reactions
- idiosyncratic reactions
Drug interactions
- dolutegravir
- dolutegravir
- enoxacin
- enoxacin
- gatifloxacin
- levodopa
- levodopa
- levofloxacin
- levofloxacin
- levothyroxine sodium
- levothyroxine sodium
- lomefloxacin
Key clinical trials
- Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy (NA)
- Ferric Citrate in Iron Deficiency Anemia During Pregnancy (PHASE3)
- Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy (NA)
- Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA) (NA)
- The Effect of Oral Iron Supplements on Insulin and Glucose Metabolism in Overweight and Obese Women (NA)
- Ovulation Incidence in Oral Contraceptive Users (PHASE3)
- South African Paediatric Surgical Outcomes Study 2 (PHASE4)
- The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron Fumarate CI brief — competitive landscape report
- Iron Fumarate updates RSS · CI watch RSS
- Pfizer portfolio CI